{
    "nctId": "NCT00193050",
    "briefTitle": "Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer",
    "officialTitle": "Phase II Trial of Induction Chemotherapy With Weekly Gemcitabine, Epirubicin, Docetaxel as Primary Treatment of Locally Advanced or Inflammatory Breast Cancer Patients",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 110,
    "primaryOutcomeMeasure": "Pathologic Complete Response (pCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\nTo be included in this study, you must meet the following criteria:\n\n* Adenocarcinoma of the breast confirmed by biopsy\n* Female Patients \\>18 years of age\n* Normal cardiac function\n* Ability to perform activities of daily living with minimal assistance\n* Chemotherapy na\u00efve or have received prior chemotherapy \\> 5 years ago\n* Adequate bone marrow, liver and kidney function\n* Be informed of the investigational nature of this study\n* Sign an informed consent form\n* Sentinel lymph node and/or axillary dissection prior to enrollment\n\nExclusion Criteria:\n\nYou cannot participate in this study if any of the following apply to you:\n\n* Life expectancy of \\< than 6 months\n* History of significant heart disease\n* Prior chemotherapy or hormonal therapy\n* Concurrent Trastuzumab therapy\n* History of significant psychiatric disorders\n* History of active uncontrolled infection\n\nPlease note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}